(Q35753453)

10 August 2017

1 reference

title

Novel antipsychotics in schizophrenia (English)

1 reference

10 August 2017

1 reference

Ann M Mortimer

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

Expert Opinion on Investigational Drugs

10 August 2017

published in

1 reference

10 August 2017

volume

13

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

315-329

1 reference

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Serotonin receptors: their key role in drugs to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Alterations in D1/D2 synergism may account for enhanced stereotypy and reduced climbing in mice lacking dopamine D2L receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Minimal effects of JL 13, a pyridobenzoxazepine derivative with an antipsychotic potential, on circulating prolactin levels in male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Tyrosine hydroxylase mRNA and protein are down-regulated by chronic clozapine in both the mesocorticolimbic and the nigrostriatal systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Regulation of GABAergic inhibition by serotonin signaling in prefrontal cortex: molecular mechanisms and functional implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Dynorphinergic gaba neurons are a target of both typical and atypical antipsychotic drugs in the nucleus accumbens shell, central amygdaloid nucleus and thalamic central medial nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Perospirone, a Novel Antipsychotic Agent, Hyperpolarizes Rat Dorsal Raphe Neurons via 5-HT1A Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Neuropharmacological profiles of a novel atypical antipsychotic, NRA0562, in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

In vitro and in vivo pharmacological profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

New 3-benzisothiazolyl and 3-benzisoxazolylpiperazine derivatives with atypical antipsychotic binding profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Behavioural pharmacology of polygalasaponins indicates potential antipsychotic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

(-)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and alpha1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Alterations in NMDA receptor subunit levels in the brain regions of rats chronically administered typical or atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Clozapine inhibits isolated N-methyl-D-aspartate receptors expressed in xenopus oocytes in a subunit specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Effect of the acute and chronic administration of the putative atypical antipsychotic drug Y-931 (8-fluoro-12- (4-methylpiperazin-1-yl)-6H-[1]benzothieno[2,3b][1,5] benzodiazepine maleate) on spontaneously active rat midbrain dopamine neurons: an in

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Effect of a novel potential atypical antipsychotic drug, Y-931, in producing dystonia in cebus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H-[1]benzothieno[2,3-b][1,5] benzodiazepine maleate).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Survival signaling and selective neuroprotection through glutamatergic transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Animal behavior models of the mechanisms underlying antipsychotic atypicality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Antipsychotic action of selective group II metabotropic glutamate receptor agonist MGS0008 and MGS0028 on conditioned avoidance responses in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Fibroblast growth factor-2 is selectively modulated in the rat brain by E-5842, a preferential sigma-1 receptor ligand and putative atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Decrease of adenylyl cyclase activity and expression by a sigma1 receptor ligand and putative atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Muscarinic mechanisms of antipsychotic atypicality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Influence of CGS 21680, a selective adenosine A(2A) agonist, on the phencyclidine-induced sensorimotor gating deficit and motor behaviour in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+‐induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Neurotensin: dual roles in psychostimulant and antipsychotic drug responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood–brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Reduced basal and phencyclidine-induced expression of heat shock protein-70 in rat prefrontal cortex by the atypical antipsychotic abaperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Increased phospholipase A2 activity in schizophrenia with absent response to niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

From pharmacotherapy to pathophysiology: emerging mechanisms of apolipoprotein D in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Antipsychotic drugs differentially modulate apolipoprotein D in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Selective amphipathic nature of chlorpromazine binding to plasma membrane bilayers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Calcium/calmodulin-dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically evoked responses in the medial prefrontal cortical pyramidal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

A pilot study of rat brain regional distribution of calcitonin, katacalcin and calcitonin gene-related peptide before and after antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Partial dopamine agonists in the treatment of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Aripiprazole: A New Atypical Antipsychotic Drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

An assessment of iloperidone for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Melperone in the treatment of neuroleptic-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.315

10.1517/13543784.13.4.315

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference